Tidepath

The GLP-1 family

Retatrutide

Also called LY3437943

Three receptors, and the third works in a different way.

Status
Not approved by the FDA, and in phase 3 trials as of October 2026.
Routes we have on file
By injection
Where doses come from
Dosing in trials
Half-life
Approximately 6 days

What it is

Retatrutide acts on the GLP-1 and GIP receptors, like tirzepatide, and adds a third: the receptor for glucagon, a hormone that raises blood sugar. That third one is the big change. Acting on it can affect how much energy the body burns (energy expenditure) and how it uses fuels such as fat and sugar (substrate metabolism), on top of the appetite and blood-sugar effects of the other two.

What makes it distinct

Retatrutide is still in trials and isn't FDA-approved. Its doses come from those trials, not from a drug label.

How levels build

Week 024681012
The same dose every week, estimated. Levels build for the first few weeks, then rise and fall in the same weekly pattern. Worked out from the half-life measured in a published trial. Retatrutide isn't FDA-approved, so this comes from a trial, not a label. An estimate of how much is left from past doses, not a blood test.

Open questions

  • Whether acting on the glucagon receptor for a long time is safe in people.
  • Its half-life (the time it takes for half a dose to clear) comes from a published study, not from an FDA label.

Worth knowing

No retatrutide product is FDA-approved, so there's no FDA label for it. Tidepath records what you tell it you're taking. It can't check what's in a vial.

Put your shot day in your calendar

A weekly reminder in the calendar you already use. It's made on your device; we never see your shot day.

More in The GLP-1 family